0 0.00612303290414891 -2.86123032903889E-05 0.00569384835479259 -0.0110300429184548 -0.0104864091559371 -0.00841201716738197 -0.0102718168812589
Sign Up Today X
Thanks for submitting the form.
Stockreport

TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026 [Yahoo! Finance]

Amgen Inc. (AMGN)  More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
PHILADELPHIA Jan. 28, 2026 /PRNewswire/ -- TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026 , taking place February 2-5 in Orlando, Florida. The annual SCOPE Summit convenes leaders from across the biopharmaceutical industry, regulatory agencies, and the clinical research ecosystem to address the evolving complexities of trial design, execution, and oversight. At this year's conference, TransCelerate and representatives from its member companies, including Amgen, Merck, and Pfizer, will participate in seven sessions addressing topics such as data collection, protocol digitization, pragmatic trial design, and integration of patient perspectives. "Clinical research is at an inflection point – tria [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026 [Yahoo! Finance]

Amgen Inc.  (AMGN) 
More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
PHILADELPHIA Jan. 28, 2026 /PRNewswire/ -- TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026 , taking place February 2-5 in Orlando, Florida. The annual SCOPE Summit convenes leaders from across the biopharmaceutical industry, regulatory agencies, and the clinical research ecosystem to address the evolving complexities of trial design, execution, and oversight. At this year's conference, TransCelerate and representatives from its member companies, including Amgen, Merck, and Pfizer, will participate in seven sessions addressing topics such as data collection, protocol digitization, pragmatic trial design, and integration of patient perspectives. "Clinical research is at an inflection point – tria [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS